BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions

Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen Fortney, Ph.D., co-founder and CEO of BioAge L Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology, inflammation and why BioAge believes its oral NLRP3 inhibitor could have applications across multiple diseases. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy…

Source: FierceBiotech